Lilly's (LLY) Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

Eli Lilly's Omvoh emerging as the first IL-23p19 to show durable disease clearance in ulcerative colitis over four years is a significant milestone for both the drug and the company. This breakthrough may enhance Lilly's competitive position in the inflammatory bowel disease market, attracting interest from investors concerned about the pipeline's potential and the stock's future performance.